Skip to main content

Table 2 Overview of the “new” TSC1 and TSC2 variants

From: Targeted Next Generation Sequencing reveals previously unidentified TSC1 and TSC2 mutations

Individual I

HaloPlex (% minor allele)

Validation (PCR-Sanger sequencing)

Index

Father

Mother

chr9 g.135804394A > G; TSC1 c.80-55 T > C (intron 3)

+/−

+/−

+/−

−/−

chr9 g.135798153C > T; TSC1 c.508 + 582G > A (intron 6)

+/−

+/−

−/−

+/−

chr9 g.135791383 T > C; TSC1 c.738-3539A > G (intron 8)

+/−

+/−

−/−

+/−

chr9 g.135765655 T > C; TSC1 c.*5967A > G (exon 23; 3′UTR)

+/−

+/−

−/−

+/−

chr 16 g.2108070C > A; TSC2 c.849-678C > A (intron 9)

+/−

+/−

−/−

+/−

chr 16 g.2119403C > T; TSC2 c.1717-1054C > T (intron 16)

+/−

+/−

−/−

+/−

chr 16 g.2124981C > G; TSC2 c.2545 + 591C > G (intron 22)

+/− (20%)

−/−*

−/−

−/−

chr 16 g.2125962C > T; TSC2 c.2639 + 69C > T (intron 23)

+/−

+/−

−/−

+/−

chr 16 g.2131815insC; TSC2 c.3814 + 19dup (intron 31)

+/− (18%)

−/−*

−/−

−/−

Individual II

HaloPlex (% minor allele)

Validation (PCR-Sanger sequencing)

Index

Sibling

Father

Mother

chr9 g.135801283C > T; TSC1 c.211-157G > A (intron 4)

+/− (31%)

+/−

+/−

+/−

−/−

chr9 g.135775735 T > C; TSC1 c.2625 + 367A > G (intron 20)

+/−

+/−

+/−

−/−

+/−

chr 9 g.135775718insA (rs36000704); TSC1 c.2625 + 383dup (intron 20)

+/−

?

?

?

?

chr 9 g.135775530 T > C (rs2284902); TSC1 c.2625 + 572 (intron 20)

+/−

+/−

+/−

+/−

−/−

chr9 g.135775415dup (rs200047376); TSC1 c.2625 + 687dup (intron 20)

+/− (35%)

+/−

+/−

+/−

−/−

chr9 g.135775427 T > C (rs6597584); TSC1 c.2625 + 675 T > G (intron 20)

+/−

+/−

+/−

+/−

−/−

Individual III

HaloPlex (% minor allele)

Validation (alle-specific PCR)

Index

Father

Mother

chr16 g.2129165, rs45464800; TSC2 c.3099C > G (exon 16)

+/− (9%)

+/−

−/−

−/−

Individual IV

HaloPlex

Validation (PCR-Sanger sequencing)

Index

Father

Mother

chr16 g.2100489 T > A; TSC2 c.225 + 2 T > A (intron 3)

+/−

+/−

−/−

−/−

chr16 g.2102256del10, rs140492671; TSC2 c.226-1086del10 (intron 3)

+/+

+/+ (ins Alu)

+/− (ins Alu)

+/+ (ins Alu)

Individual V

HaloPlex

Validation (PCR-Sanger sequencing)

Index

Father

Mother

chr9 g.135820146delACTCATA; TSC1 c.-15894_-15888del

+/−

+/−

−/−

+/−

chr9 g.135763459 T > A; 3′ TSC1 exon 23

+/−

+/−

−/−

+/−

Individual VI

HaloPlex (% minor allele)

Validation (alle-specific PCR)

Index

Father

Mother

chr16 g.2127477G > A; TSC2 c.2838-122G > A (intron 25)

+/− (12%)

+/−

−/−

−/−

Individual VII

HaloPlex (% minor allele)

Validation (PCR-Sanger sequencing)

chr16 g.2101947C > T, rs139385485; TSC2 c.226-1396 T > C (intron 3)

+/− (18%)

+/−

chr16 g.2102256del10, rs140492671; TSC2 c.226-1086del10 (intron 3)

+/− (10%)

+/− (ins Alu)

chr16 g.2105289 T > C, rs77037371; TSC2 c.482-114 T > C (intron 5)

+/− (70%)

+/−

chr16 g.2105335C > G, rs2516734; TSC2 c.482-68C > G (intron 5)

+/− (70%)

+/−

chr16 g.2113125A > G; TSC2 c.1443 + 71A > G (intron 14)

+/−

+/−

chr16 g.2113464C > T; TSC2 c.1443 + 410C > T (intron 14)

+/−

+/−

chr16 g.2120785C > T; TSC2 c.1839 + 206C > T (intron 17)

+/−

+/−

chr16 g.2130697G > A; TSC2 c.3610 + 319G > A (intron 30)

+/−

+/−

  1. Variants identified by HaloPlex custom capture NGS without an rs-number in dbSNP132 are listed per individual. The results of the subsequent PCR-Sanger sequencing and/or allele-specific PCR validation are shown for the relevant individual and any available family members. Results for variants identified with a skewed allelic ratio (minor allele detected in <40% or >60% of the sequence reads) are also shown. * indicates a discrepancy between the HaloPlex result and the validation experiment. ? indicates that the nucleotide change identified by HaloPlex could not be confirmed by Sanger sequencing due to the presence of polyA:T stretches. Pathogenic mutations are indicated in bold.